The Latest Cardiac and Vascular News
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from two additional analyses from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), as well as an analysis of patients hospitalized for heart failure with […]
Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil on December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 SEQUOIA-HCM Continuing with Results Expected in 2H 2023; Patient Screening for Cohort 4 of REDWOOD-HCM Closed with Data Expected in 1H 2023 […]
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 31, 2022 it granted stock options to purchase an aggregate of 202,500 shares of common stock to 20 new employees, whose […]
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2022 it granted stock options to purchase an aggregate of 99,000 shares of common stock to 10 new employees, whose […]
Treatment with Aficamten Associated with Significant Improvements in Symptoms and Quality of Life Additional Data Presented in Poster Session Shows Patients with Worsening Heart Failure and LVEF ≤30% Have Disproportionately High Risk of Heart Failure Hospitalization SOUTH SAN FRANCISCO, Calif., Oct. […]
New Analysis Demonstrates Successful Reduction or Withdrawal of Standard of Care Therapies in Patients Treated with Aficamten SOUTH SAN FRANCISCO, Calif., Sept. 30, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today presented new data on the reduction and withdrawal […]
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 11th, 2022 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: […]
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 31, 2022 it granted stock options to purchase an aggregate of 186,400 shares of common stock to 23 new employees, whose […]
Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil Scheduled for December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 Company Revises 2022 Financial Guidance; Reduces Projected Spending for 2022 SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE […]
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 29, 2022 it granted stock options to purchase an aggregate of 88,200 shares of common stock to 11 new employees, whose […]
![Life Molecular Imaging Secures FDA Fast Track Designation for [18F]Florbetaben in Diagnosing Cardiac AL and ATTR Amyloidosis](https://cardiacvascularnews.com/wp-content/uploads/2025/01/Life-molecular-imaging-e1737489511884-90x60.png)